A second small-molecule EGFR tyrosine kinase inhibitor, erlotinib, was also found to have anti-tumor activity in phase II trials [11-13], but, unlike gefitinib, demonstrated improved survival in a placebo controlled phase III study. Here, EGFR is linked to neoplasm.